Gallbladder Cancer

Amit Mahipal, Anuhya Kommalapati, Sri Harsha Tella, Gaurav Goyal, Tushar C Patel, Candice A. Bookwalter, Sean P. Cleary, Christopher L. Hallemeier, Rondell Graham

Research output: Chapter in Book/Report/Conference proceedingChapter


Gallbladder cancer (GBC) is the most common malignant tumor of the biliary tract representing 80-95% of biliary tract cancers worldwide. The disease has a striking variability in the incidence, being most common in some countries such as Chile, North India, and Japan, and less common in western countries such as the United States. Most cases are diagnosed at late stages due to vague symptoms, and only 10-30% of patients are candidates for curative resection. Given the rarity of the disease in many parts of the world, contemporary clinical data are limited to a few clinical trials. Moreover, patients with GBC are often combined with other biliary tract cancers in clinical trials. Nevertheless, the treatment of gallbladder cancer has evolved over the last decade with an increased emphasis on the use of therapies such as intensity-modulated radiotherapy (IMRT), molecular targeted therapy, and combination chemotherapy. In addition, randomized controlled trials are evaluating the roles of chemotherapy and molecular-targeted therapy in the management of the disease. In this chapter, we detail the contemporary clinical management of gallbladder cancer with a special focus on the latest developments in the field.

Original languageEnglish (US)
Title of host publicationEvaluation and Management of Liver Masses
PublisherSpringer International Publishing
Number of pages34
ISBN (Electronic)9783030466992
ISBN (Print)9783030466985
StatePublished - Jan 1 2020


  • Cisplatin
  • Gallbladder cancer
  • Gemcitabine
  • Immunotherapy
  • Intensity-modulated radiotherapy
  • Targeted therapy

ASJC Scopus subject areas

  • Medicine(all)


Dive into the research topics of 'Gallbladder Cancer'. Together they form a unique fingerprint.

Cite this